Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Tax Provisions (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Tax Provisions for 16 consecutive years, with $12.0 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 247.88% to $12.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.5 million through Dec 2025, up 426.82% year-over-year, with the annual reading at $34.5 million for FY2025, 426.82% up from the prior year.
  • Tax Provisions hit $12.0 million in Q4 2025 for Ligand Pharmaceuticals, down from $23.9 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $38.7 million in Q4 2022 to a low of -$13.5 million in Q2 2024.
  • Historically, Tax Provisions has averaged $4.4 million across 5 years, with a median of $2.1 million in 2021.
  • Biggest five-year swings in Tax Provisions: crashed 1629.97% in 2024 and later soared 2764.83% in 2025.
  • Year by year, Tax Provisions stood at $4.1 million in 2021, then skyrocketed by 847.43% to $38.7 million in 2022, then plummeted by 102.82% to -$1.1 million in 2023, then plummeted by 643.54% to -$8.1 million in 2024, then soared by 247.88% to $12.0 million in 2025.
  • Business Quant data shows Tax Provisions for LGNDZ at $12.0 million in Q4 2025, $23.9 million in Q3 2025, and $6.4 million in Q2 2025.